赛诺菲胰岛素原料药项目在北京经济技术开发区启动

Core Points - Sanofi announced the launch of its insulin raw material drug project in Beijing Economic-Technological Development Area, marking a significant investment of €1 billion, the largest in Beijing's pharmaceutical industry since the 14th Five-Year Plan [1] - The new facility is expected to address the increasing demand for insulin in China, where diabetes prevalence rose from 10.9% in 2013 to 12.4% in 2018-2019, highlighting the urgent need for stable and sustainable insulin supply [1] - The production site will cover nearly 60,000 square meters and is set to be fully operational by 2032, incorporating advanced production processes, digitalization, and AI for efficiency and quality control [2] Company and Industry Summary - The new base will enhance supply chain resilience and create high-quality jobs, contributing to broader social and economic benefits in China [1] - Sanofi's investment is part of its "China Solution" strategy, aiming to establish a high-quality production network across its existing facilities in Beijing, Shenzhen, and Hangzhou [2] - The facility will implement sustainable production measures, including advanced energy management and carbon reduction processes, aligning with global standards [2]